Shanghai, China

Fanhong Xu

This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignee: Shanghai Institute of Biological Products Co., Ltd.. Active years: 2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Fanhong Xu. Retrieved from https://idiyas.com/inventor/fanhong-xu

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


% Patents Active = 100.0


Average Co-Inventor Count = 11.0

ph-index = 1


Company Filing History:


Years Active: 2024

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Fanhong Xu: Innovator in Monoclonal Antibody Development

Introduction

Fanhong Xu is a prominent inventor based in Shanghai, China. He is known for his significant contributions to the field of biotechnology, particularly in the development of humanized monoclonal antibodies. His work has the potential to impact the treatment of various diseases related to the HER3 antigen.

Latest Patents

Fanhong Xu holds a patent for an anti-HER3 humanized monoclonal antibody. This innovative antibody binds to the HER3 antigen, demonstrating high affinity and biological activity while maintaining low immunogenicity. Its structural stability makes it a promising candidate for drug development aimed at preventing or treating HER3-related diseases.

Career Highlights

Fanhong Xu is affiliated with the Shanghai Institute of Biological Products Co., Ltd., where he has been instrumental in advancing research and development in monoclonal antibody therapies. His expertise in this area has positioned him as a key figure in the biotechnology sector.

Collaborations

Fanhong Xu has collaborated with notable colleagues, including Aidong Qu and Hongyuan Liang. These partnerships have fostered a collaborative environment that enhances innovation and research outcomes.

Conclusion

Fanhong Xu's work in developing the anti-HER3 humanized monoclonal antibody exemplifies his commitment to advancing medical science. His contributions are paving the way for new therapeutic options in the treatment of HER3-related diseases.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…